Australian Dollar: Testing major support with rebound risk against US Dollar – Societe Generale
Societe Generale analysts describe AUD/USD extending its pullback after breaking below the May trough around 0.7070 and retesting the 200-DMA near 0.6870/0.6830, aligned with March lows. They stress this zone as key support, noting November 2025’s correction also held there. With risk tone crucial, a short-term rebound is possible while 0.7070/0.7090 caps upside.
Key moving averages and range levels
"AUD/USD has experienced an extended pullback after breaking below the May trough around 0.7070."
"The pair has recently retested the 200-DMA around 0.6870/0.6830, which also coincides with the March lows."
"Notably, the correction in November 2025 found support near this MA."
"If AUD/USD defends the support zone around 0.6870/0.6830, a short-term rebound cannot be ruled out."
"The recent lower high near 0.7070/0.7090 may act as an important hurdle."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BoJ’s Takata calls for nimble, data-dependent rate hikes rather than a fixed pace
AI Infrastructure Stocks Shed $4.2 Trillion—Is the “Shovel Seller Feast” Over?
Since June, Caterpillar has dropped by 44%, and Oklo has plummeted by 49%. Analysts point to the root cause: investors have been speculating on traditional industrial stocks as growth stocks, resulting in severely overvalued prices. Another key factor behind the sell-off is the uncertainty of data center regulatory policies following the U.S. midterm elections. The fundamentals remain resilient—Caterpillar has a backlog of orders totaling $78 billion, and several companies have secured revenue growth through 2027.

Johnson & Johnson (JNJ.US) plans to spend $3.4 billion to acquire Ollin, expanding its presence in the retinal disease treatment sector.
According to sources familiar with the matter, Johnson & Johnson may announce a deal as early as Monday to acquire Texas-based biotech company Ollin Biosciences for up to $3.4 billion.
As market forces battle each other, the yen is caught in a tug-of-war between bulls and bears! Goldman Sachs bets on a comeback while Morgan Stanley predicts a fall to 162
As the USD/JPY exchange rate approaches the key 160 level again, Morgan Stanley and Goldman Sachs have expressed sharply divergent views on the yen’s outlook. This highlights that forecasting the yen’s exchange rate is becoming increasingly challenging amid multiple conflicting forces.

